IL131126A - Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof - Google Patents

Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof

Info

Publication number: IL131126A
Authority: IL; Israel
Prior art keywords: incidence; compositions; reducing; necrotizing enterocolitis; preparation
Prior art date: 1997-02-21

Application number

IL13112698A

Other languages

English (en)

Other versions

IL131126A0 (en

Original Assignee

Abbott Lab

Univ Tennessee Res Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-21

Filing date

1998-02-19

Publication date

2003-04-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL131126(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-10-03 Priority claimed from US08/943,576 external-priority patent/US6080787A/en

1998-02-19 Application filed by Abbott Lab, Univ Tennessee Res Corp filed Critical Abbott Lab

1998-02-19 Priority to IL15049098A priority Critical patent/IL150490A0/xx

2001-01-28 Publication of IL131126A0 publication Critical patent/IL131126A0/xx

2003-04-10 Publication of IL131126A publication Critical patent/IL131126A/xx

Links

206010051606 Necrotising colitis Diseases 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
208000004995 necrotizing enterocolitis Diseases 0.000 title abstract 2
201000006195 perinatal necrotizing enterocolitis Diseases 0.000 title abstract 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 4
235000021342 arachidonic acid Nutrition 0.000 abstract 2
229940114079 arachidonic acid Drugs 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract 1
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract 1
102000002322 Egg Proteins Human genes 0.000 abstract 1
108010000912 Egg Proteins Proteins 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
235000020669 docosahexaenoic acid Nutrition 0.000 abstract 1
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract 1
235000013345 egg yolk Nutrition 0.000 abstract 1
210000002969 egg yolk Anatomy 0.000 abstract 1
150000002632 lipids Chemical class 0.000 abstract 1
235000020667 long-chain omega-3 fatty acid Nutrition 0.000 abstract 1
235000010598 long-chain omega-6 fatty acid Nutrition 0.000 abstract 1
235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 abstract 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract 1
230000002195 synergetic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Fats And Perfumes (AREA)
Silicates, Zeolites, And Molecular Sieves (AREA)

IL13112698A 1997-02-21 1998-02-19 Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof IL131126A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
IL15049098A IL150490A0 (en)	1997-02-21	1998-02-19	A process for the production of an enteral formula containing arachidonic acid and/or docosahexaenoic acid in the form of phospholipids and formula obtained by same

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US80470097A	1997-02-21	1997-02-21
US82531497A	1997-03-28	1997-03-28
US08/943,576 US6080787A (en)	1997-02-21	1997-10-03	Methods for reducing the incidence of necrotizing enterocolitis
PCT/US1998/003235 WO1998036745A2 (en)	1997-02-21	1998-02-19	Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis

Publications (2)

Publication Number	Publication Date
IL131126A0 IL131126A0 (en)	2001-01-28
IL131126A true IL131126A (en)	2003-04-10

Family

ID=27420004

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13112698A IL131126A (en)	1997-02-21	1998-02-19	Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof

Country Status (23)

Country	Link
US (1)	US6306908B1 (id)
EP (1)	EP1039892B1 (id)
JP (1)	JP2001516343A (id)
CN (1)	CN1200701C (id)
AT (1)	ATE265207T1 (id)
AU (1)	AU732903B2 (id)
BR (1)	BR9807443A (id)
CA (1)	CA2281706C (id)
DE (1)	DE69823548T2 (id)
DK (1)	DK1039892T3 (id)
ES (1)	ES2219871T3 (id)
HU (1)	HUP0300236A3 (id)
ID (1)	ID22744A (id)
IL (1)	IL131126A (id)
NO (1)	NO994052L (id)
NZ (1)	NZ337039A (id)
PL (1)	PL343902A1 (id)
PT (1)	PT1039892E (id)
RU (1)	RU2199317C2 (id)
SK (1)	SK112399A3 (id)
TR (1)	TR199902023T2 (id)
TW (1)	TWI230607B (id)
WO (1)	WO1998036745A2 (id)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL121165A0 (en) *	1997-06-26	1997-11-20	Yissum Res Dev Co	Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6180671B1 (en) *	1998-03-10	2001-01-30	Beth Israel Deaconess Medical Center, Inc.	Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
DE19836339B4 (de) *	1998-08-11	2011-12-22	N.V. Nutricia	Kohlenhydratmischung
US20090274660A1 (en) *	1999-08-17	2009-11-05	Immunopath Profile, Inc.	Pluripotent therapeutic compositions and uses thereof
US6596302B2 (en) *	2000-04-13	2003-07-22	Abbott Laboratories	Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
GB0016045D0 (en) *	2000-06-29	2000-08-23	Laxdale Limited	Therapeutic combinations of fatty acids
KR101195574B1 (ko) *	2002-09-24	2012-10-30	산토리 홀딩스 가부시키가이샤	아라키돈산을 단독으로 또는 도코사헥사엔산과의 조합으로함유하는 인지 능력 향상용 조성물
US7323206B1 (en)	2003-03-04	2008-01-29	B. Braun Medical Inc.	Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
GB0311081D0 (en) *	2003-05-14	2003-06-18	Btg Internat Limted	Treatment of neurodegenerative conditions
WO2004112507A1 (en) *	2003-06-23	2004-12-29	Nestec S.A.	Infant or follow-on formula
KR20060030860A (ko) *	2003-06-24	2006-04-11	유니버시티 오브 캔사스 메디컬 센터	유아 조제유
EP2324828A1 (en) *	2003-08-18	2011-05-25	BTG International Limited	Treatment for neurodegenerative conditions
EP1597978A1 (en) *	2004-05-17	2005-11-23	Nutricia N.V.	Synergism of GOS and polyfructose
US8252769B2 (en)	2004-06-22	2012-08-28	N. V. Nutricia	Intestinal barrier integrity
RU2429718C2 (ru) *	2004-06-22	2011-09-27	Н.В. Нютрисиа	Повышение целостности барьера у больных с вич
EP1721611A1 (en) *	2005-04-21	2006-11-15	N.V. Nutricia	Nutritional supplement with oligosaccharides for a category of HIV patients
US7862808B2 (en)	2004-07-01	2011-01-04	Mead Johnson Nutrition Company	Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
EP1656839A1 (en)	2004-11-11	2006-05-17	N.V. Nutricia	Nutrition containing lipid blend
GB0425932D0 (en) *	2004-11-25	2004-12-29	Btg Int Ltd	Structured phospholipids
GB0504362D0 (en) *	2005-03-02	2005-04-06	Btg Int Ltd	Cytokine modulators
GB0504333D0 (en) *	2005-03-02	2005-04-06	Btg Int Ltd	Treatment of cytokine dysregulation
US20060233762A1 (en) *	2005-04-15	2006-10-19	Mcmahon Robert J	Method for treating or preventing systemic inflammation in formula-fed infants
US7303745B2 (en)	2005-04-15	2007-12-04	Bristol-Myers Squibb Company	Method for preventing or treating the development of respiratory allergies
CN101163415B (zh) *	2005-04-21	2013-03-13	N.V.努特里奇亚	用于hiv患者的营养补充剂
CN101166428B (zh) *	2005-04-27	2015-03-04	努特里希亚公司	含脂类和不易消化的糖的营养品
CA2645645C (en)	2005-05-23	2015-07-14	Massachusetts Institute Of Technology	Compositions containing pufa and methods of use thereof
JP2007063219A (ja) *	2005-09-01	2007-03-15	Juntendo	新生児壊死性腸炎疾患予防剤
EP1776877A1 (en) *	2005-10-21	2007-04-25	N.V. Nutricia	Method for stimulating the intestinal flora
US20070166354A1 (en) *	2005-10-26	2007-07-19	Bridget Barrett-Reis	Method of reducing the risk of retinopathy of prematurity in preterm infants
US7829126B2 (en)	2005-10-26	2010-11-09	Abbott Laboratories	Infant formulas containing docosahexaenoic acid and lutein
US20070149617A1 (en) *	2005-11-14	2007-06-28	Deckelbaum Richard J	Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
BRPI0620465A2 (pt) *	2005-12-23	2011-11-16	Nutricia Nv	uso de uma composição
US20080003330A1 (en) *	2006-06-30	2008-01-03	Ricardo Rueda	Infant formulas for early brain development
US20080003329A1 (en) *	2006-06-30	2008-01-03	Ricardo Rueda	Enriched infant formulas
US7867542B2 (en) *	2006-11-02	2011-01-11	Ach Food Companies, Inc.	Non-flammable release composition
CN101801200B (zh)	2007-09-17	2014-10-29	康奈尔大学	用于预防或治疗胃肠病症的支链脂肪酸
KR101354547B1 (ko)	2007-10-09	2014-01-22	엔지모테크 리미티드	위장 장애의 치료 및 장 발달 및 성숙의 촉진용의 지질 조성물
UY31410A1 (es) *	2007-10-30	2009-05-29		Composicion que comprende acidos grasos poliinsaturados y carbon vegetal activado
US8975299B2 (en)	2007-11-01	2015-03-10	Enzymotec Ltd.	Lipid mixture for infant nutrition
WO2009085388A2 (en)	2007-12-20	2009-07-09	Abbott Laboratories	Stable nutritional powder
US8361534B2 (en) *	2007-12-20	2013-01-29	Abbott Laboratories	Stable nutritional powder
EP2100897A1 (en) *	2008-01-30	2009-09-16	BNLfood Investments SARL	Lecithin based composition and its use in food
WO2009096772A1 (en) *	2008-02-01	2009-08-06	N.V. Nutricia	Composition for stimulating natural killer cell activity
US9737213B1 (en) *	2009-03-24	2017-08-22	Vioptix, Inc.	Using an oximeter probe to detect intestinal ischemia
CN102368913A (zh) *	2009-04-01	2012-03-07	雀巢产品技术援助有限公司	降低肥胖的风险
TW201112967A (en) *	2009-09-16	2011-04-16	Abbott Lab	Dryblended nutritional powders
TW201121431A (en) *	2009-12-01	2011-07-01	Abbott Lab	Soy protein-based nutritional formula with superior stability
TWI492744B (zh)	2009-12-04	2015-07-21	Abbott Lab	使用類胡蘿蔔素調節早產兒發炎症之方法
EP2509429A1 (en) *	2009-12-08	2012-10-17	Nestec S.A.	Infant formula with probiotics and milk fat globule membrane components
CA2786710C (en)	2010-01-19	2018-10-09	Abbott Laboratories	Nutritional formulas containing synbiotics
WO2011094548A1 (en)	2010-01-29	2011-08-04	Abbott Laboratories	Aseptically packaged nutritional liquids comprising hmb
US9693577B2 (en)	2010-01-29	2017-07-04	Abbott Laboratories	Method of preparing a nutritional powder comprising spray dried HMB
SG182812A1 (en)	2010-01-29	2012-09-27	Abbott Lab	Nutritional emulsions comprising calcium hmb
TWI526161B (zh)	2010-06-10	2016-03-21	亞培公司	包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
EP2397038A1 (en)	2010-06-21	2011-12-21	Abbott Laboratories	Early programming of brain function through soy protein feeding
WO2012009426A1 (en)	2010-07-13	2012-01-19	Abbott Laboratories	High tolerance infant formula including hydrolyzed protein
EP2422629A1 (en)	2010-08-23	2012-02-29	Abbott Laboratories	Methods for enhancing cognition and/or memory using maltodextrins
WO2012027287A1 (en)	2010-08-24	2012-03-01	Abbott Laboratories	Nutritional products including pea protein hydrolysates
EP2608681B1 (en)	2010-08-24	2015-09-16	Abbott Laboratories	Nutritional products having improved organoleptic properties
ES2558112T3 (es)	2010-12-29	2016-02-02	Abbott Laboratories	Productos nutricionales que incluyen un nuevo sistema lipídico que incluye monoglicéridos
NZ611807A (en)	2010-12-31	2015-02-27	Abbott Lab	Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
DK2658399T4 (da)	2010-12-31	2024-03-25	Abbott Lab	Ernæringssammensætninger omfattende humane mælkeoligosaccharider til anvendelse i behandling og/eller forebyggelse af enterisk rotavirus-infektion
MX356184B (es)	2010-12-31	2018-05-17	Abbott Lab	Fórmulación pediátrica sintética que comprende un probiótico.
BR112013016929A2 (pt)	2010-12-31	2019-09-24	Abbott Lab	oligossacarídeos de leite humano para promover o crescimento de bactérias benéficas
ES2804258T3 (es)	2010-12-31	2021-02-05	Abbott Lab	Procedimientos para reducir la incidencia de estrés oxidativo usando oligosacáridos de leche humana, vitamina C y agentes antiinflamatorios
EP3338784B1 (en)	2010-12-31	2020-07-22	Abbott Laboratories	Human milk oligosaccharides for modulating inflammation
EP2658400A2 (en)	2010-12-31	2013-11-06	Abbott Laboratories	Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
MX388089B (es)	2010-12-31	2025-03-19	Abbott Lab	Metodos para usar los oligosacaridos de leche humana para mejorar la salud respiratoria de las vias aereas.
WO2013012989A2 (en)	2011-07-19	2013-01-24	The Trustees Of Columbia University In The City Of New York	Method and system for production of hydrogen and carbon monoxide
DK2734210T3 (en)	2011-07-22	2018-01-22	Abbott Lab	GALACTOOLIGOSACCHARIDES FOR THE PREVENTION OF DAMAGE TO AND / OR PROMOTION OF HEALING OF THE MAVE GAS CHANNEL
US10639319B2 (en)	2011-08-29	2020-05-05	Abbott Laboratories	Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2013101516A1 (en)	2011-12-29	2013-07-04	Abbott Laboratories	Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using extracted genomic dna
SG11201403693SA (en)	2011-12-29	2014-07-30	Abbott Lab	Methods for reducing microbial contamination of dryblended powdered nutritional compositions
CN110301646A (zh)	2012-03-27	2019-10-08	雅培制药有限公司	用于使用人乳寡糖调节细胞介导的免疫的方法
WO2013170189A1 (en)	2012-05-11	2013-11-14	Abbott Laboratories	Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow
DK2708147T3 (da)	2012-09-14	2020-05-18	Abbott Lab	Fremgangsmåder til forøgelse af hjernefunktionalitet under anvendelse af 2-fucosyl-lactose
EP2708145B1 (en)	2012-09-14	2016-05-04	Abbott Laboratories	Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals
EP2708146A1 (en)	2012-09-17	2014-03-19	Abbott Laboratories, Inc.	Nutritional composition for pregnant women with a beneficial glucose and insulin profile
WO2014078544A1 (en)	2012-11-14	2014-05-22	Abbott Laboratories	Compositions and methods for improving the long term safety of powdered infant formulas
WO2014099904A1 (en)	2012-12-17	2014-06-26	Abbott Laboratories	Methods for enhancing motor function, enhancing functional status and mitigating muscle weakness in a subject
EP2745705A1 (en)	2012-12-18	2014-06-25	Abbott Laboratories	Nutritional use of human milk oligosaccharides
WO2014100022A1 (en)	2012-12-18	2014-06-26	Abbott Laboratories	Dietary oligosaccharides to enhance learning and memory
MY187609A (en)	2012-12-18	2021-10-04	Abbott Lab	Human milk oligosaccharides to ameliorate symptoms of stress
CN104853621A (zh)	2012-12-20	2015-08-19	雅培制药有限公司	使用人乳寡糖用于调节炎症的营养制剂
EP2745708A1 (en)	2012-12-24	2014-06-25	Abbott Laboratories, Inc.	Antidepressant effect of ß-hydroxy-ß-methylbutyrate
US20160037817A1 (en)	2013-03-12	2016-02-11	Abbott Laboratories	Composition comprising a multifunctional viscosity modifying agent
MX2015013000A (es)	2013-03-15	2015-12-01	Abbott Lab	Metodos de mantenimiento y mejora de la funcion muscular.
CA2903561C (en)	2013-03-15	2017-09-26	Abbott Laboratories	Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, casein phosphopeptide, and protein
CN105263321B (zh)	2013-03-28	2018-07-27	哥伦比亚大学纽约管理委员会	用omega-3甘油酯再灌注促进对用于移植的供体器官的保护
US20160136192A1 (en)	2013-06-10	2016-05-19	Abbott Laboratories	Methods and compositions for enhancing cognitive performance
WO2015048646A1 (en)	2013-09-30	2015-04-02	Abbott Laboratories	Protein powder
SG11201502037QA (en)	2013-10-11	2015-05-28	Abbott Lab	Nutritional composition for pregnant women with a beneficial glucose and insulin profile
CN103558296B (zh) *	2013-10-18	2015-03-04	中国农业大学	一种基于脂肪酸检测的动物源性饲料原料鉴别方法
CN104623637A (zh)	2013-11-07	2015-05-20	健能隆医药技术（上海）有限公司	Il-22二聚体在制备静脉注射药物中的应用
US10568896B2 (en)	2013-11-19	2020-02-25	Abbott Laboratories	Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
EP2888950A1 (en)	2013-12-24	2015-07-01	Abbott Laboratories	Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment
WO2015105981A2 (en)	2014-01-09	2015-07-16	Abbott Laboratories	Conditional essentiality of hmb
HK1231398A1 (zh)	2014-04-08	2017-12-22	Abbott Laboratories	使用人乳寡糖增强对病原体的粘膜先天免疫反应和/或检测的方法
DE102015101273A1 (de) *	2015-01-29	2016-08-04	Eberhard Karls Universität Tübingen Medizinische Fakultät	Prophylaxe und Behandlung von frühgeburtlichkeitsassoziierten Entwicklungsstörungen
WO2017181143A1 (en)	2016-04-15	2017-10-19	Generon (Shanghai) Corporation, Ltd.	Use of il-22 in treating necrotizing enterocolitis
RU2665947C1 (ru) *	2017-07-13	2018-09-05	Атикат Магомедхановна Герейханова	Способ лечения некротического энтероколита
CA3141763A1 (en)	2019-06-07	2020-12-10	Abbott Laboratories	Nutritional ingredient with flow and antifoam properties
EP4106794A4 (en)	2020-02-19	2024-03-20	Evive Biotechnology (Shanghai) Ltd	METHOD FOR TREATING TRANSPLANT AND HOST DISEASE
MX2022012509A (es)	2020-04-06	2022-11-07	Abbott Lab	Formulaciones nutricionales para modular citocinas inducidas por la respiracion.
CN112137998A (zh) *	2020-10-10	2020-12-29	上海交通大学医学院附属新华医院	一种活性成分在制备防治坏死性小肠结肠炎药物中的应用
WO2022177965A1 (en)	2021-02-16	2022-08-25	Abbott Laboratories	Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2022226311A1 (en)	2021-04-23	2022-10-27	Abbott Laboratories	Nutritional compositions comprising human milk oligosaccharides and a designed lipid component for improving lung function
WO2022266058A1 (en)	2021-06-14	2022-12-22	Abbott Laboratories	Methods and compositions for treating gas
WO2023159093A1 (en)	2022-02-16	2023-08-24	Abbott Laboratories	Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2024064327A1 (en)	2022-09-22	2024-03-28	Abbott Laboratories	Human milk oligosaccharides for enhancing blood-brain barrier function

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3374914D1 (en)	1982-04-12	1988-01-28	Univ Texas	Methods and compositions for treating gastro-intestinal ulcer diesease
US4670285A (en)	1982-08-06	1987-06-02	The University Of Toronto Innovations Foundation	Infant formula
US4784861A (en)	1986-11-24	1988-11-15	Cca Industries, Inc.	Weight-control formulation
US5032585A (en)	1987-02-17	1991-07-16	Board Of Regents, The University Of Texas System	Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US4950656A (en)	1987-02-17	1990-08-21	Board Of Regents, The University Of Texas System	Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5043329A (en)	1987-02-17	1991-08-27	Board Of Regents, University Of Texas System	Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US4918063A (en) *	1987-02-17	1990-04-17	Board Of Regents, The University Of Texas System	Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5000975A (en)	1988-12-29	1991-03-19	American Home Products Corporation	Randomized palm oil fat composition for infant formulas
US5116819A (en) *	1989-05-05	1992-05-26	Clintec Nutrition Co.	Enteral diet for patients with pulmonary disease
US5658767A (en)	1991-01-24	1997-08-19	Martek Corporation	Arachidonic acid and methods for the production and use thereof
WO1992012711A1 (en)	1991-01-24	1992-08-06	Martek Corporation	Microbial oil mixtures and uses thereof
WO1993020717A2 (en) *	1992-04-13	1993-10-28	Research Corporation Technologies, Inc.	Reducing gastrointestinal irritation in infant nutrition
DE4407939A1 (de) *	1993-03-15	1994-09-22	Sueddeutsche Kalkstickstoff	Verfahren zur Herstellung von fett- und cholesterinreduzierten pulverförmigen Produkten auf Eibasis
FR2721481B1 (fr) *	1994-06-27	1996-09-06	Inst Rech Biolog Sa	Nouvelles compositions diététiques à base de phospholipides et leur utilisation comme complément nutritionnel.
DK0784437T3 (da)	1994-10-05	1999-04-19	Milupa Gmbh & Co Kg	Phospholipidholdig fedtblanding med LCP-fedtsyrer
JPH09201A (ja) *	1995-06-23	1997-01-07	Akikuni Yakida	炎症性腸疾患用食品
US5917068A (en)	1995-12-29	1999-06-29	Eastman Chemical Company	Polyunsaturated fatty acid and fatty acid ester mixtures free of sterols and phosphorus compounds
US5790138A (en)	1996-01-16	1998-08-04	Monolithic System Technology, Inc.	Method and structure for improving display data bandwidth in a unified memory architecture system

1998
- 1998-02-19 ES ES98906580T patent/ES2219871T3/es not_active Expired - Lifetime
- 1998-02-19 WO PCT/US1998/003235 patent/WO1998036745A2/en not_active Ceased
- 1998-02-19 AT AT98906580T patent/ATE265207T1/de not_active IP Right Cessation
- 1998-02-19 HU HU0300236A patent/HUP0300236A3/hu unknown
- 1998-02-19 RU RU99119892/14A patent/RU2199317C2/ru not_active IP Right Cessation
- 1998-02-19 CN CNB988043726A patent/CN1200701C/zh not_active Expired - Fee Related
- 1998-02-19 EP EP98906580A patent/EP1039892B1/en not_active Revoked
- 1998-02-19 ID IDW990897A patent/ID22744A/id unknown
- 1998-02-19 PT PT98906580T patent/PT1039892E/pt unknown
- 1998-02-19 PL PL98343902A patent/PL343902A1/xx unknown
- 1998-02-19 SK SK1123-99A patent/SK112399A3/sk unknown
- 1998-02-19 TR TR1999/02023T patent/TR199902023T2/xx unknown
- 1998-02-19 IL IL13112698A patent/IL131126A/xx not_active IP Right Cessation
- 1998-02-19 AU AU61769/98A patent/AU732903B2/en not_active Ceased
- 1998-02-19 CA CA002281706A patent/CA2281706C/en not_active Expired - Fee Related
- 1998-02-19 DE DE69823548T patent/DE69823548T2/de not_active Revoked
- 1998-02-19 DK DK98906580T patent/DK1039892T3/da active
- 1998-02-19 JP JP53687198A patent/JP2001516343A/ja active Pending
- 1998-02-19 BR BR9807443-1A patent/BR9807443A/pt not_active IP Right Cessation
- 1998-02-19 NZ NZ337039A patent/NZ337039A/en unknown
- 1998-04-03 TW TW087102492A patent/TWI230607B/zh not_active IP Right Cessation
1999
- 1999-08-23 NO NO994052A patent/NO994052L/no not_active Application Discontinuation
2000
- 2000-05-12 US US09/570,299 patent/US6306908B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NZ337039A (en)	2001-06-29
ATE265207T1 (de)	2004-05-15
TR199902023T2 (xx)	2001-09-21
US6306908B1 (en)	2001-10-23
CN1200701C (zh)	2005-05-11
RU2199317C2 (ru)	2003-02-27
HUP0300236A2 (hu)	2003-06-28
DE69823548D1 (de)	2004-06-03
BR9807443A (pt)	2000-04-25
ES2219871T3 (es)	2004-12-01
AU6176998A (en)	1998-09-09
JP2001516343A (ja)	2001-09-25
CN1269718A (zh)	2000-10-11
WO1998036745A3 (en)	2002-10-03
CA2281706A1 (en)	1998-08-27
IL131126A0 (en)	2001-01-28
PL343902A1 (en)	2001-09-10
NO994052D0 (no)	1999-08-23
CA2281706C (en)	2008-08-05
DK1039892T3 (da)	2004-08-30
EP1039892B1 (en)	2004-04-28
AU732903B2 (en)	2001-05-03
DE69823548T2 (de)	2005-02-24
SK112399A3 (en)	2000-12-11
TWI230607B (en)	2005-04-11
NO994052L (no)	1999-10-20
WO1998036745A2 (en)	1998-08-27
ID22744A (id)	1999-12-09
HUP0300236A3 (en)	2003-09-29
HK1034033A1 (en)	2001-10-12
PT1039892E (pt)	2004-09-30
EP1039892A2 (en)	2000-10-04

Legal Events

Date	Code	Title
2003-10-31	FF	Patent granted
2003-12-10	KB	Patent renewed
2004-03-28	KB	Patent renewed
2008-03-23	KB	Patent renewed
2012-02-29	KB	Patent renewed
2016-09-29	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
IL131126A0 (en)	2001-01-28	Methods and compositions for reducing the incidence of necrotizing enterocolitis
Vidgren et al.	1997	Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
AR005556A1 (es)	1999-06-23	Formula enteral, un suplemento nutricional que contiene una composicion de trigliceridos, trigliceridos, y un procedimiento para preparar esteres de acidos grasos a partir de una mezcla de lipidos
AU677318B2 (en)	1997-04-17	A lipidic composition intended for use as a food or in food products
DK1121115T4 (da)	2011-01-10	PUFA-tilskud
DE69622722D1 (de)	2002-09-05	Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselssyndroms
PL190841B1 (pl)	2006-02-28	Syntetyczna kompozycja lipidowa i jej zastosowanie do wytwarzania pokarmu dla niemowląt
EP2255668A3 (en)	2012-04-04	Production and Use of a Polar Lipid-Rich Fraction Containing Omega-3 and/or Omega-6 Highly Unsaturated Fatty Acids from Microbes, Genetically Modified Plant Seeds and Marine Organisms
TW200744463A (en)	2007-12-16	Nutritional supplement containing long-chain polyunsaturated fatty acids
KR940018091A (ko)	1994-08-16	불포화 지방산을 포함하는 처방
CO5550401A2 (es)	2005-08-31	Mezclas lipidas y productos alimenticios que contienen acido graso oleico y acidos grasos omega-6 diseñados para aumentar el nivel de lipido intramiocelular
DK1027831T3 (da)	2006-02-20	Stabiliseret fedtstofsammensætning, fremgangsmåde til fremstilling deraf og ernæringsprodukt indeholdende denne
ATE454820T1 (de)	2010-01-15	Neuartige fettpulver
Hassam	1977	The influence of α-linolenic acid (18: 3ω3) on the metabolism of γ-linolenic acid (18: 3ω6) in the rat
JPWO2004108870A1 (ja)	2006-07-20	油脂臭の新規脱臭法及びその組成物
Ilyasoglu	2017	Production of structured lipid with a low omega-6/omega-3 fatty acids ratio by enzymatic interesterification
OGUNLEIYE et al.	1990	Effect of fish oil and safflower oil in common Japanese diet on human plasma fatty acid composition
Yeo et al.	2000	Plasma phospholipids, including plasmalogens, after consumption of diets enriched in long-chain n-3 fatty acids
Sandoval et al.	2017	Omega-3 in the Prevention of Cardiovascular Diseases
Nettleton	2006	Omega-3 and Omega-6 Polyunsaturated Fatty Acids in the American Diet.
Milin et al.	2002	Polar lipid fatty acid composition changes induced by lipid supplemented diets associated with mice liver regeneration